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Abstract
Backgroud: Patients with chronic inflammatory bowel disease (IBD) are at an increased risk of
colorectal cancer (CRC) and it is estimated that one in six persons diagnosed with IBD will develop
CRC. This fact suggests that genetic variations in inflammatory response genes may act as CRC
disease risk modifiers.
Methods: In order to test this hypothesis we investigated a series of polymorphisms in 6 genes
(NOD2, DLG5, OCTN1, OCTN2, IL4, TNFα) associated with the inflammatory response on a
group of 607 consecutive newly diagnosed colorectal cancer patients and compared the results to
controls (350 consecutive newborns and 607 age, sex and geographically matched controls).
Results: Of the six genes only one polymorphism in TNFα(-1031T/T) showed any tendency to be
associated with disease risk (64.9% for controls and 71.4% for CRC) which we further
characterized on a larger cohort of CRC patients and found a more profound relationship between
the TNFα -1031T/T genotype and disease (64.5% for controls vs 74.7% for CRC cases above 70
yrs). Then, we investigated this result and identified a suggestive tendency, linking the TNFα -
1031T/T genotype and a previously identified change in the CARD15/NOD2 gene (OR = 1.87; p =
0,02 for CRC cases above 60 yrs).
Conclusion: The association of polymorphisms in genes involved in the inflammatory response
and CRC onset suggest that there are genetic changes capable of influencing disease risk in older
persons.
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Background
Biological and epidemiological data indicate a clear asso-
ciation between chronic inflammation and malignancy
[1]. Patients with inflammatory bowel disease (IBD),
including Crohn disease (CD) and ulcerative colitis (UC),
are at increased risk of developing colorectal cancer [2].
Epidemiological and linkage studies strongly suggest the
involvement of genetic factors in IBD, especially those
associated with inflammation.
Recently, it has been shown that the NOD2/CARD15
(nucleotide oligomerisation domain 2/caspase activating
recruitment domain 15) gene is implicated in the suscep-
tibility to Crohn's disease [3,4]. NOD2/CARD15 is
expressed intracellularly in monocytes/macrophages and
granulocytes, where it activates the nuclear factor NF-κB,
making it responsive to bacterial lipopolysaccharides
which culminate in the activation of apoptosis [5].
Patients harbouring mutant NOD2 alleles are presumably
deficient in the activation of NF-κB and consequently the
appropriate response to bacterial infection [5-7]. Among
patients with CD, the frequency of C-insertion mutation
in exon 11 of NOD2 is about three times higher compared
to control populations [4].
In a previous investigation, we found a significant associ-
ation between the NOD2 frameshift constitutional muta-
tion (3020insC) and the risk of colorectal cancer in
patients diagnosed above the age of 50 years (OR = 2.23;
p = 0.0046) [8].
The association between IBD and polymorphisms in
other inflammation-related genes involved in the innate
immune response like DLG5 [9], IL-4 [10], OCTN [11],
TNFα [12] have been reported but their relationship to
disease risk requires further investigation. Together, the
associations between polymorphisms in inflammatory
response genes and IBD make them attractive candidate
susceptibility genes for colorectal cancer since approxi-
mately 1:6 individuals with IBD will develop malignancy
[13]. In addition, there is sufficient evidence to suggest
that remodeling of the immune system with age may also
alter cancer risk [14] and consequently alterations in the
activity of TNFα may become more pronounced with age.
In the present study, we evaluated whether single nucle-
otide polymorphisms (SNPs) within a number of inflam-
matory response genes are associated with an increased
risk of colorectal cancer. Ten SNPs in the following six
genes: NOD2 (2140 C/T, 2722 G/C), DLG5 (113 G/A),
OCTN1 (1672 C/T), OCTN2 (-207 G/C), IL4 (-590 C/T)
and TNFα (-308 G/A, -857 C/T, -863 C/A, -1031 T/C) were
screened in a consecutive series of colorectal cancer
patients using a two-staged approach.
Methods
The investigation was performed in two stages, first to pre-
select candidate genetic variations by determinating the
frequency of any alteration in an unselected colorectal
cancer population compared to the newborn controls.
The second, depth analysis was performed on specifically
matched control subjects to the colorectal cancer group.
For the first stage of the study a group of 350 consecutive,
newly diagnosed collected patients affected by colorectal
adenocarcinomas from the clinical hospital SPSK-2 Szc-
zecin and a group of 350 control subjects (consecutive
newborns from the clinical hospitals of Szczecin) were
studied.
During the second stage of the investigation a further 257
consecutive, newly diagnosed colorectal cancer (CRC)
patients from Szczecin were combined with the first 350
CRC patients to give a final 607 cases and compared to
607 age, year of birth, sex and geographically matched
healthy controls from families negative for a cancer family
history. The CRC patients – 316 males and 291 females –
were collected between the years 1996 and 2006 with the
average age of disease diagnosis being 63.2 (range 27–92
yrs). Definite diagnosis of Crohn disease has not been
established in any CRC patients.
The adult controls were initially identified during the pop-
ulation genetic cancer screening programme performed in
West-Pomerania from 2000–2001. Family doctors and
community nurses collected questionnaires with cancer
family histories from 1 258000 (85%) of the inhabitants.
Before inclusion in the study, all selected adults were ver-
ified for their pedigree/clinical data at cancer genetic out-
patient clinics that were part of our centre.
This investigation was approved by the Institutional Eth-
ics review committee of the Pomeranian Academy of Med-
icine, Szczecin and informed consent was obtained from
all participants prior to enrolment into the study.
DNA samples were extracted from peripheral blood lym-
phocytes derived from CRC patients and matched con-
trols or from umbilical cord blood of newborns according
to method of Miller et al [15].
Cases and controls were genotyped by using the PCR-
RFLP method described by others for the following SNPs:
TNFα -857, -863, -1031 [16], TNFα -308 [17], IL-4 -590C/
T [18], NOD2 2140C/T, 2722G/C [19], 3020insC [8],
DLG5113G/A [9]. Genotyping of OCTN1 1672C/T was
performed using the following primers F: TAGTCTGACT-
GTCCTGATTGGAAGC, R: TGCTTATTCTCCCTAAG-
GCATTTTGG followed by AluI restriction fragment length
polymorphism (RFLP) analysis.BMC Cancer 2008, 8:112 http://www.biomedcentral.com/1471-2407/8/112
Page 3 of 7
(page number not for citation purposes)
For OCTN2 -207G/C polymorphism analysis the primers
F: CCGCTCTGCCTGCCAGCGGG, R: CAAGACCGTC-
CGCGGAGGGTAGG and a HpaII RFLP were used. For
each SNP studied a random number were taken and sub-
jected to direct sequencing analysis to reduce the risk that
the genotypes were a result of genotyping error. The con-
cordance between the samples taken for DNA sequencing
compared to PCR-RFLP analysis was 100 percent. If sam-
ples failed to amplify after three attempts the sample and
its partner were left out of the analysis such that all analy-
ses were performed on matched pairs.
Statistical analysis included a comparison of the preva-
lence of the genotype frequency in cases versus controls.
Odds ratios were generated from two-by-two contingency
tables and statistical significance was determined using
Fisher's exact test.
Each genetic variant studied was in Hardy-Weinberg equi-
librium.
To estimate the genotype/disease interaction the patient
group was stratified by age and logistic regression model-
ling was undertaken [31]. All interaction analyses were
based on the genotype comparison using a codominant
model.
Results
The study was performed in two stages to ensure that the
Polish population frequencies of the chosen polymor-
phisms were no different to that reported in the NCBI SNP
database [32].
During the first stage of the study ten polymorphisms in
six genes were analysed and no significant differences in
the frequencies of nine of the variants was observed in the
CRC group compared to the newborn control population.
Only one polymorphism (TNFα -1031 T/T) showed a ten-
dency towards being over-represented in the CRC group
compared to the newborn control population. The fre-
quency of the TNFα -1031 T/T genotype was 71.4% in the
CRC group against 64.9% in the newborn control popula-
tion.
To better define the relationship between the TNFα -
1031T/T SNP and cancer risk a further 257 consecutively
collected CRC patients were assayed for the presence of
the T/T genotype and the results compared to an adult
Table 1: Screening of polymorphisms tested for association with CRC between cases and sex, age and geographically matched 
controls.
Gene/Change Age groups Genotype Matched controls n = 607 CRC cases n = 607 OR (95% CI) p-value
NOD2/3020insC consecutive WT/WT 558 (91.9%) 544 (89.6%) 1.00 0.065
WT/insC 49 (8.1%) 60 (9.9%) 1.26 (0.85–1.87)
insC/insC 0 (0%) 3 (0.5%) NA
≤ 50 WT/WT 91 (91.9%) 94 (95%) 1.00 0.38
WT/insC 8 (8.1%) 5 (5%) 0.60 (0.19–1.92)
>50 WT/WT 467 (91.9%) 450 (88.6%) 1.00 0.038
WT/insC 41 (8.1%) 55 (10.8%) 1.39 (0.91–2.14)
insC/insC 0 (0%) 3 (0.6%) NA
>60 WT/WT 350 (91.4%) 335 (87.5%) 1.00 0.042
WT/insC 33 (8.6%) 45 (11.8%) 1.43 (0.89–2.29)
insC/insC 0 (0%) 3 (0.8%) NA
>70 WT/WT 168 (90.3%) 159 (85.5%) 1.00 0.15
WT/insC 18 (9.7%) 27 (14.5%) 1.59 (0.84–3.01)
TNFα/-1031 T/C consecutive T/T 411 (67.7%) 431 (71%) 1.00 0.14
T/C 170 (28%) 161 (26.5%) 0.89 (0.69–1.15)
C/C 26 (4.3%) 15 (2.5%) 0.54 (0.28–1.04)
≤50 T/T 71 (71.7%) 63 (63.6%) 1.00 0.42
T/C 24 (24.2%) 32 (32.3%) 1.53 (0.81–2.90)
C/C 4 (4%) 4 (4%) 1.19 (0.28–5.01)
>50 T/T 340 (66.9%) 368 (72.4%) 1.00 0.04
T/C 146 (28.7%) 129 (25.4%) 0.80 (0.61–1.06)
C/C 22 (4.3%) 11 (2.2%) 0.45 (0.22–0.95)
>60 T/T 252 (65.8%) 276 (72.1%) 1.00 0.059
T/C 115 (30%) 99 (25.9%) 0.76 (0.55–1.05)
C/C 16 (4.2%) 8 (2.1%) 0.44 (0.18–1.05)
>70 T/T 120 (64.5%) 139 (74.7%) 1.00 0.084
T/C 60 (32.3%) 43 (23.1%) 0.61 (0.38–0.96)
C/C 6 (3.2%) 4 (2.1%) 0.57 (0.15–2.08)BMC Cancer 2008, 8:112 http://www.biomedcentral.com/1471-2407/8/112
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control population that has been matched for year of
birth, age, sex and domicile (Table 1). The results reveal
that the -1031T/T genotype in the CRC group overall
when compared to the control population was not signif-
icantly different in its frequency (71.0% vs 67.7%).
When the consecutively collected CRC group was strati-
fied for age of diagnosis, there appeared to be an associa-
tion of the TNFα -1031T/T SNP with later ages of disease
diagnosis (see Table 1).
Previously we have shown in the Polish population that
the NOD2 3020insC mutation is associated with CRC risk
[8], which remained in this new analysis (Table 1). A com-
bined analysis of patients harbouring the NOD2 muta-
tion and the TNFα -1031T/T SNP was performed. The
combined analysis was performed on 607 CRC patients
and 607 matched healthy controls in order to determine
if the TNFα -1031 T/T SNP acts in association with the
NOD2 3020insC change. From this analysis a total of 41
cases were identified in the CRC group compared to 27 in
the control group, which revealed an over-representation
of the two SNPs in the CRC group compared to the con-
trol group (OR 1.50, p = 0.45). The average age of disease
onset in persons harbouring both polymorphisms com-
pared to those only harbouring the TNFα -1031T/T
change was found to 69.8 years of age (range 48–84) com-
pared to non-carriers 65.3 years of age (range 30–92),
which was not statistically significant. Conversely, we
observed a trend toward a protective effect in that there
was an under-representation of the TNFα -1031 C/C and
NOD2 3020insC negative carriers in the CRC population
(OR 0.49, p = 0.45) (see Table 2).
When stratified by age, the association between the TNFα
-1031 T/T and NOD2 3020insC carriers and disease
became more apparent (see Table 3) with age thereby pro-
viding further evidence that these two polymorphisms are
associated with later onset disease.
Discussion
In the present study, we compared the frequency of a
series of polymorphisms in different inflammatory
response genes associated with IBD (DLG5, IL-4, OCTN,
TNFα and NOD2) in colorectal cancer cases against con-
trols. The results indicate that the TNFα -1031 TT variant
frequency had a tendency to be over-represented in the
CRC population compared to an unmatched newborn
control population and compared to stringently matched
controls. In addition, the association observed in the CRC
group compared to the matched controls became more
apparent when the CRC patients were stratified by age.
The increasing association of the TNFα -1031 T/T geno-
type with the age of diagnosis of colorectal cancer sug-
gests that there is a link between age-related remodeling
of the immune system [14] which results in a greater pre-
disposition to disease with aging in the presence of this
polymorphism.
Other polymorphisms were also investigated within the
TNFα promoter region of the gene (-857 C/T, -308 G/A, -
238 G/A) and they appeared to confer no protective influ-
ence on colorectal cancer risk, a finding which is consist-
ent with other observations [20-23]. Nevertheless
associations of the TNFα promoter -1031 polymorphism
together with the -308 and -238 polymorphisms have also
been made with respect to invasive breast carcinoma [24]
and an increased risk of gastric cancer [25]. Other malig-
nancies have also been investigated but no significant dif-
ferences in the distribution of the -1031 T/T variant have
been found in nasopharyngeal carcinoma [26] or in
malignant melanoma [27]. There is no information about
the relationship between the TNFα -1031 T/T polymor-
phism and colorectal cancer and further studies are neces-
sary to confirm above results.
We have previously reported an association between the
NOD2 3020insC mutation and colorectal cancer risk [8]
which has been confirmed in two other reports [28,29]
but remains controversial as two other reports failed to
identify any association [13,30]. In this current report,
instead of using general population controls to determine
whether the frequency of the NOD2 3020insC mutation
was over-represented in our CRC population we used an
age, year of birth, sex and domicile matched control pop-
ulation and identified a similar association between this
mutation and disease. An age dependent trend was also
observed for CRC patients over 50 years of age.
Table 2: Combined analysis of TNFα -1031T/C and NOD2 3020insC in consecutively collected CRC cases compared to matched 
control subjects.
NOD2 WT/WT NOD2 WT/insC + insC/insC
Gene Controls CRC OR (95%CI) Controls CRC OR (95% CI)
TNFα T/T 384 390 1.00 27 41 1.50 (0.90–2.49)
TNFα T/C 150 142 0.93 (0.71–1.22) 20 19 0.94 (0.49–1.79)
TNFα C/C 24 12 0.49 (0.24–1.00) 2 3 1.48 (0.25–8.97)
p = 0.45BMC Cancer 2008, 8:112 http://www.biomedcentral.com/1471-2407/8/112
Page 5 of 7
(page number not for citation purposes)
By undertaking a combined analysis of carriers of the
NOD2 3020insC mutation who have the TNFα -1031T/T
genotype and comparing their frequency in the CRC pop-
ulation to the matched control population a more pro-
nounced interaction emerges. There appears to be an over-
representation of NOD2 3020insC and TNFα -1031T/T
carriers in the CRC group compared to the matched con-
trol group suggesting that it is the combined effect of the
two polymorphisms that is particularly important and
that their influence becomes more profound with age as
evidenced by the increasing over-representation of the
two polymorphisms in older CRC patients.
Our studies have several obvious limitations: the size of
the study population is relatively small and some stratifi-
cations were performed that increased the likelihood of
false positive outcomes as a result of the multiple compar-
ison testing. Finally, additional larger investigations using
other larger patient groups in ours as well as other popu-
lations are required to unequivocally determine the role
of these SNPs on CRC risk.
Conclusion
In conclusion, it appears that independently both the
TNFα-1031T/T and the NOD2 3020insC polymorphisms
may act as low risk modifiers of colorectal cancer risk.
Together, the evidence presented in this report suggests an
additive effect of the two polymorphisms that becomes
increasingly important with advancing age with respect to
the risk of CRC. Studies on a larger cohort of colorectal
cancer cases and matched controls are necessary to clarify
the relationship between the TNFα -1031T/T and NOD2
3020insC polymorphisms and CRC.
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